Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of PARP inhibitor resistance in ovarian cancer

9 Dec 2019

Abstract excerpt

PURPOSE OF REVIEW: To summarize recently discovered PARP inhibitor resistance mechanisms and highlight the clinical relevance of these findings to date. RECENT FINDINGS: A predominant mechanism of acquired PARP inhibitor resistance in homologous recombination-deficient cancers is the acquisition of homologous recombination proficiency as a consequence of secondary genetic or epigenetic events, such as secondary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31815769
DOI: 10.1097/gco.0000000000000600

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of PARP inhibitor resistance in ovarian cancerPMID 31815769Read ↗

Clinical approaches to overcome PARP inhibitor resistanceSemantic proximity Read ↗

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian CancerSemantic proximity Read ↗

Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancerSemantic proximity Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor ResistanceSemantic proximity Read ↗

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancerSemantic proximity Read ↗

PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathwaySemantic proximity Read ↗

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read ↗

PARP inhibitors: Clinical utility and possibilities of overcoming resistanceSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapySemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP inhibitor resistance: the underlying mechanisms and clinical implicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.